

KYMRIAH[®] ▼ (tisagenlecleucel) dispersion for intravenous infusion

Patient Educational Leaflet

Important Information for You (the Patient), Guardians, and Caregivers

Your doctor will give you a copy of the Package Leaflet for KYMRIAH (also known as tisagenlecleucel), a KYMRIAH Patient Alert Card, and the KYMRIAH Patient Educational Leaflet (this document).

Please read and keep the Package Leaflet.

Please read the Patient Alert Card in its entirety, carry the card with you at all times and show it to all health care providers.

Please read and keep this Patient Educational Leaflet to remind you of the signs and symptoms of cytokine release syndrome, neurological events, and infections that require immediate medical attention.

If you have any questions about tisagenlecleucel, please speak to your doctors or nurses.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

If you get side effects with any medication you are taking, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the information leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the patient safety information (PSI) tool at <https://psi.novartis.com>.

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com

What is tisagenlecleucel?

Tisagenlecleucel is a medicine made from your own white blood cells, and is used to treat:

- **B-cell acute lymphoblastic leukaemia (B-cell ALL):** a form of cancer that affects some types of white blood cells. The medicine can be used in children and young adults up to and including 25 years of age with this cancer.
- **Diffuse large B-cell lymphoma (DLBCL):** a form of cancer that affects some types of white blood cells, mostly in the lymph nodes. The medicine can be used in adults (18 years of age or older) with this cancer.
- **Follicular lymphoma (FL):** a form of cancer that affects some types of white blood cells called lymphocytes, mostly in the lymph nodes. The medicine can be used in adults (18 years of age or older) with this cancer.

What should I expect before getting tisagenlecleucel?

Collection of blood to manufacture tisagenlecleucel

- Since tisagenlecleucel is made from your own white blood cells, your doctor will take some of your blood using a catheter (a small tube) placed in your vein; this procedure is called “leukapheresis”.
- Some of your white blood cells are separated from your blood and the rest of your blood is returned to your vein. This can take 3 to 6 hours and may need to be repeated.
- Your collected white blood cells are frozen and sent away to the manufacturing site to make tisagenlecleucel.

Manufacturing tisagenlecleucel

- Tisagenlecleucel is a treatment that is manufactured specifically for you. Manufacturing time may vary and typically takes several weeks.
- There are situations where tisagenlecleucel cannot be successfully manufactured and be given to you. In some cases, a second manufacturing of tisagenlecleucel may be attempted.
- There are also instances where the final manufactured product falls outside the pre-specified acceptance criteria for tisagenlecleucel (i.e., the product is out-of-specification). However, if your treating physician assesses that the anticipated benefit outweighs the risks associated with this out-of-specification product, the final product may still be provided for infusion at your physician’s request.

Bridging therapy/potential disease worsening

- While tisagenlecleucel is being manufactured, additional therapy (known as ‘bridging therapy’) may be needed to stabilise your cancer. This may induce side effects which can be severe or life-threatening. The treating physician will inform you about potential side effects of this therapy.
- While you await tisagenlecleucel manufacture, the underlying disease may worsen and progress.

Lymphodepleting chemotherapy

- Shortly before you are administered tisagenlecleucel, your doctor may give you a type of treatment called lymphodepleting chemotherapy (also called conditioning chemotherapy) over a few days to prepare your body for tisagenlecleucel infusion.

What are the possible side effects after tisagenlecleucel infusion that I should be aware of?

- Tell **your doctor immediately** if you get any of the following side effects after the tisagenlecleucel infusion. They usually happen in the first 8 weeks after the infusion, but can also develop later:
- High fever and chills. These may be symptoms of a serious condition called cytokine release syndrome. Other symptoms of cytokine release syndrome are difficulty breathing, nausea, vomiting, diarrhoea, loss of appetite, fatigue, muscle pain, joint pain, swelling, low blood pressure, fast heartbeat, headache, heart, lung, and kidney failure and liver injury. These symptoms almost always occur within the first 14 days after infusion.
- Neurological events such as altered thinking or decreased consciousness, loss of contact with reality, confusion, agitation, seizures, difficulty speaking and understanding speech, and difficulty walking. These may be symptoms of a condition called immune effector cell-associated neurotoxicity syndrome (ICANS).
- Feeling warm, fever, chills, or shivering, sore throat or mouth ulcers, which may be signs of an infection. Some infections may be life-threatening or fatal.

These are not all the possible side effects of tisagenlecleucel. For other potential side effects, refer to the Package Leaflet. You may need to be hospitalised for side effects.

Monitoring/possible hospitalisation

- Plan to stay within 2 hours’ travel from the hospital where you were treated for at least 4 weeks after you have been given tisagenlecleucel.
- Your doctor will recommend that you return to the hospital daily for at least 10 days and will consider whether you need to stay at the hospital as an inpatient for the first 10 days after infusion. This is so your doctor can check if your treatment is working and help you if you have any side effects, such as potential cytokine release syndrome, neurological events and other toxicities.
- After the first 10 days following tisagenlecleucel infusion, you will be monitored as per your doctor’s discretion.

Additional important instructions for you about using tisagenlecleucel

- Take your temperature twice a day for 3-4 weeks after administration of tisagenlecleucel. If temperature is elevated, see your doctor immediately.
- Due to the potential of tisagenlecleucel to cause problems such as altered or decreased consciousness, confusion, and seizures in the 8 weeks following infusion, you should not drive, use machines, or take part in activities that require alertness.
- Do not donate blood, organs, tissues or cells.

Effect on HIV testing

- There may be an effect on the results of some types of HIV tests: treatment with tisagenlecleucel may result in a false-positive test result; ask your doctor about this.

Important information for health care professionals:

- This patient has received an infusion of Kymriah (tisagenlecleucel), a CAR-T cell therapy for: _____ [please fill in indication as appropriate] on _____ [please add date of infusion].
- Following tisagenlecleucel treatment, development of cytokine release syndrome and neurological events can occur, typically within the first few weeks after infusion; however, later occurrence might happen.
- Please contact his/her treating oncologist before giving steroids or cytotoxic medications. Consult with his/her treating oncologist for the treatment of the patient.

Contact details for KYMRIAH treating physician

- Name: _____ Centre/City: _____
- Telephone number(s): _____